PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25349647-7	2014	IL-28B-CC-genotype patients treated with protease inhibitor-based triple-therapy consisting of Boceprevir, Simeprevir, Telaprevir or Vaniprevir showed odds of 3.38, 14.66, 7.84 and 2.91, respectively.	Simeprevir	107-117	interferon lambda 3	Homo sapiens	0-6	
28520373-0	2012	Simeprevir Therapy and IFNL3 Genotype Simeprevir is a hepatitis C virus (HCV) protease inhibitor used in combination with other drugs to treat chronic hepatitis genotype 1 or 4 infection (1).	Simeprevir	38-48	interferon lambda 3	Homo sapiens	23-28	
28520373-5	2012	The FDA-approved drug label for simeprevir contains information regarding a genetic variant near the IFNL3 gene (a C to T change; rs12979860), which is a strong predictor of response to peginterferon alfa and ribavirin treatment.	Simeprevir	32-42	interferon lambda 3	Homo sapiens	101-106	
28520373-7	2012	However, patients of all IFNL3 genotypes had highest SVR rates when being treated with regimens that included simeprevir.	Simeprevir	110-120	interferon lambda 3	Homo sapiens	25-30	
28884930-5	2018	Among the 6 patients receiving lead-in injections, viral relapse occurred in 2 patients who had an unfavorable IFN-lambda3-related gene single nucleotide polymorphism allele; both patients had been previously treated with simeprevir, and HCV carrying NS5A-L31V/Y93H mutations had emerged after DCV/ASV.	Simeprevir	222-232	interferon lambda 3	Homo sapiens	111-122	
28261382-17	2017	CONCLUSION: Both TVR- and SMV-based triple therapies can be successfully used to treat patients aged 66 years or older with genotype 1b chronic hepatitis C. Genotyping of the IL28B indicates a potential to achieve SVR in these difficult-to-treat elderly patients.	Simeprevir	26-29	interferon lambda 3	Homo sapiens	175-180	
26991414-7	2016	RBV dosage affected SVR dose-dependently in patients with the IL28B non-TT genotype treated with SMV triple therapy.	Simeprevir	97-100	interferon lambda 3	Homo sapiens	62-67	
26668696-8	2015	Patients in the SMV group were older, had higher serum HCV RNA levels, lower hemoglobin, higher prevalence of unfavorable interleukin-28B (IL28B) genotype (rs8099917), and poorer response to previous PEG-IFN and RBV treatment.	Simeprevir	16-19	interferon lambda 3	Homo sapiens	122-137	
26668696-8	2015	Patients in the SMV group were older, had higher serum HCV RNA levels, lower hemoglobin, higher prevalence of unfavorable interleukin-28B (IL28B) genotype (rs8099917), and poorer response to previous PEG-IFN and RBV treatment.	Simeprevir	16-19	interferon lambda 3	Homo sapiens	139-144	
26095167-9	2015	CONCLUSIONS: Considering the effectiveness and safety, simeprevir-based triple therapy will continue to be a useful treatment option in Japan for treatment-naive or prior relapse patients with a favorable IL28B genotype.	Simeprevir	55-65	interferon lambda 3	Homo sapiens	205-210